drugset / Trial / NCT00216528
A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate symptomatic remission rate in patients with schizophrenia using long acting risperidone microspheres
Timeline
- Start
- 2005-07
- Primary completion
- —
- Completion
- 2007-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | 25 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 37.5 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 50 mg | Intramuscular |